Intraocular Methotrexate in Ocular Diseases Other Than Primary Central Nervous System Lymphoma

Paul W. Hardwig; Jose S. Pulido; Jay C. Erie; Keith H. Baratz; Helmut Buettner

doi:10.1016/j.ajo.2006.06.002

Intraocular Methotrexate in Ocular Diseases Other Than Primary Central Nervous System Lymphoma

Paul W. Hardwig, Jose S. Pulido, Jay C. Erie, Keith H. Baratz, Helmut Buettner

Ophthalmology

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Purpose: To investigate whether intravitreal methotrexate could be safely administered and improve vision in patients with ocular disease other than primary central nervous system lymphoma (PCNSL). Design: A retrospective, small-case series. Methods: Patients with various clinical conditions were treated with intravitreal methotrexate (cumulative dose ≤400 μg). Visual acuity and clinical examination were recorded to assess the safety and efficacy of the injection. Results: Of 16 study eyes, final visual acuity was improved in seven, remained stable in five, and decreased in four. There was no observed toxicity attributable to methotrexate in any case. Conclusion: Preservation of visual acuity in 12 of 16 study eyes suggests that a 400-μg intravitreal injection is safe in ocular disease other than PCNSL. The loss of acuity in four eyes with advanced preexisting pathology may be just as likely attributable to the natural history of the disease as to intraocular methotrexate.

Original language	English (US)
Pages (from-to)	883-885
Number of pages	3
Journal	American journal of ophthalmology
Volume	142
Issue number	5
DOIs	https://doi.org/10.1016/j.ajo.2006.06.002
State	Published - Nov 2006

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ajo.2006.06.002

Cite this

@article{e8f18ee0a0a14ff28dd237f21da13366,

title = "Intraocular Methotrexate in Ocular Diseases Other Than Primary Central Nervous System Lymphoma",

abstract = "Purpose: To investigate whether intravitreal methotrexate could be safely administered and improve vision in patients with ocular disease other than primary central nervous system lymphoma (PCNSL). Design: A retrospective, small-case series. Methods: Patients with various clinical conditions were treated with intravitreal methotrexate (cumulative dose ≤400 μg). Visual acuity and clinical examination were recorded to assess the safety and efficacy of the injection. Results: Of 16 study eyes, final visual acuity was improved in seven, remained stable in five, and decreased in four. There was no observed toxicity attributable to methotrexate in any case. Conclusion: Preservation of visual acuity in 12 of 16 study eyes suggests that a 400-μg intravitreal injection is safe in ocular disease other than PCNSL. The loss of acuity in four eyes with advanced preexisting pathology may be just as likely attributable to the natural history of the disease as to intraocular methotrexate.",

author = "Hardwig, {Paul W.} and Pulido, {Jose S.} and Erie, {Jay C.} and Baratz, {Keith H.} and Helmut Buettner",

note = "Funding Information: Supported in part by Research to Prevent Blindness, Inc, New York, New York, and by the Mayo Foundation, Rochester, Minnesota. Copyright: Copyright 2011 Elsevier B.V., All rights reserved.",

year = "2006",

month = nov,

doi = "10.1016/j.ajo.2006.06.002",

language = "English (US)",

volume = "142",

pages = "883--885",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Intraocular Methotrexate in Ocular Diseases Other Than Primary Central Nervous System Lymphoma

AU - Hardwig, Paul W.

AU - Pulido, Jose S.

AU - Erie, Jay C.

AU - Baratz, Keith H.

AU - Buettner, Helmut

N1 - Funding Information: Supported in part by Research to Prevent Blindness, Inc, New York, New York, and by the Mayo Foundation, Rochester, Minnesota. Copyright: Copyright 2011 Elsevier B.V., All rights reserved.

PY - 2006/11

Y1 - 2006/11

N2 - Purpose: To investigate whether intravitreal methotrexate could be safely administered and improve vision in patients with ocular disease other than primary central nervous system lymphoma (PCNSL). Design: A retrospective, small-case series. Methods: Patients with various clinical conditions were treated with intravitreal methotrexate (cumulative dose ≤400 μg). Visual acuity and clinical examination were recorded to assess the safety and efficacy of the injection. Results: Of 16 study eyes, final visual acuity was improved in seven, remained stable in five, and decreased in four. There was no observed toxicity attributable to methotrexate in any case. Conclusion: Preservation of visual acuity in 12 of 16 study eyes suggests that a 400-μg intravitreal injection is safe in ocular disease other than PCNSL. The loss of acuity in four eyes with advanced preexisting pathology may be just as likely attributable to the natural history of the disease as to intraocular methotrexate.

AB - Purpose: To investigate whether intravitreal methotrexate could be safely administered and improve vision in patients with ocular disease other than primary central nervous system lymphoma (PCNSL). Design: A retrospective, small-case series. Methods: Patients with various clinical conditions were treated with intravitreal methotrexate (cumulative dose ≤400 μg). Visual acuity and clinical examination were recorded to assess the safety and efficacy of the injection. Results: Of 16 study eyes, final visual acuity was improved in seven, remained stable in five, and decreased in four. There was no observed toxicity attributable to methotrexate in any case. Conclusion: Preservation of visual acuity in 12 of 16 study eyes suggests that a 400-μg intravitreal injection is safe in ocular disease other than PCNSL. The loss of acuity in four eyes with advanced preexisting pathology may be just as likely attributable to the natural history of the disease as to intraocular methotrexate.

UR - http://www.scopus.com/inward/record.url?scp=33750059779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750059779&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2006.06.002

DO - 10.1016/j.ajo.2006.06.002

M3 - Article

C2 - 17056381

AN - SCOPUS:33750059779

SN - 0002-9394

VL - 142

SP - 883

EP - 885

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 5

ER -

Intraocular Methotrexate in Ocular Diseases Other Than Primary Central Nervous System Lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this